No Data
No Data
Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
BioXcel Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants
BioXcel Therapeutics Commences Public Offering Of Shares Of Its Common Stock And Accompanying Warrants; No Terms Disclosed
BioXcel Therapeutics Announces Proposed Public Offering
Express News | BioXcel Therapeutics- as of Nov 18, ‘431 Patent Has Been Accepted for Listing in FDA Approved Drug Products With Therapeutic Equivalence Evaluations
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1